• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cardiovascular therapeutics >Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy
【24h】

Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy

机译：尽管有先前的他汀类药物单一疗法，但无论有无2型糖尿病的高危患者，依泽替米贝/辛伐他汀10/20 mg与瑞舒伐他汀10 mg的脂质改变功效均未得到充分控制

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy. Methods: Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients with (n = 182) and without T2DM (n = 434). Results: EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apo B in the overall study population and within both subgroups. Numerically, greater between-treatment reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients with T2DM versus those without T2DM. A significant interaction (P= 0.015) was seen for LDL-C indicating that patients with T2DM achieved larger between-group reductions versus those without T2DM. Conclusions: Switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior lipid reductions in patients with/without T2DM.
机译：目的：这项事后分析比较了在使用他汀类药物而患有/不患有2型糖尿病（T2DM）的不受控制的高危高胆固醇血症患者中，切换至依泽替米贝/辛伐他汀10/20 mg（EZE / SIMVA）或瑞舒伐他汀10 mg（ROSUVA）的效果单一疗法。方法：尽管使用他汀类药物但LDL-C≥100和≤190mg / dL升高的高冠心病高危患者（n = 618）被随机分配为1：1双盲EZE / SIMVA 10/20 mg或ROSUVA 10毫克，持续6周。根据以下两项中的≥1将患者分类为T2DM：T2DM诊断，抗糖尿病药物或FPG≥126mg / dL。这项分析评估了有（n = 182）和没有T2DM（n = 434）患者中脂质相对于基线的变化百分比。结果：在整个研究人群和两个亚组中，EZE / SIMVA在降低LDL-C，TC，非HDL-C和apo B方面比ROSUVA更有效。从数字上看，与没有T2DM的患者相比，T2DM患者的LDL-C，TC，非HDL-C和载脂蛋白B的治疗间减少更大。对于LDL-C，存在显着的相互作用（P = 0.015），这表明与没有T2DM的患者相比，T2DM的患者组间减少幅度更大。结论：相对于ROSUVA 10 mg，转换为EZE / SIMVA 10/20 mg可以在患有或不患有T2DM的患者中降低脂质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号